Siren, L.L.C. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002005245

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 109 positions · Total reported value $4.21B · Top-10 concentration 47.5% · Updated 2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

Turnover: 55.7% · 15 new · 36 cut · 22 exited

Active Share (vs S&P 500): 97.6% · vs QQQ: 97.6% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.5% · vs SPY -15.6% · Prev Value $4.93B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.2% · vs SPY -6.4% · Latest Value $4.21B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Siren, L.L.C. disclosed 109 equity positions with a combined reported value of $4.21B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were SRRK ($453.00M), KYMR ($311.32M), ERAS ($193.48M). By sector, the heaviest allocations are Health Care 94.0%, Technology 4.2%. Versus the prior quarter, allocation shifted toward Health Care (+1.9pp) and away from Financials (-0.7pp), Other (-0.7pp).

Versus the prior quarter, Siren, L.L.C. opened 15 new positions, trimmed 36 and fully exited 22, a turnover rate of 55.7% of positions. The portfolio's overlap with the prior quarter was 72% of names.

The largest new positions opened in Q3 2026 were VNDA ($38.40M), ASND ($29.62M), DARE ($15.20M).

Of the 22 positions fully exited versus the prior quarter, the largest were DFTX ($66.77M), CRNX ($53.17M), COF ($34.43M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VNDA ADARx Pharmaceuticals, Inc. · $38.40M
  • ASND ASCENDIS PHARMA A/S · $29.62M
  • DARE Yarrow Bioscience, Inc. · $15.20M
  • SKHY SK HYNIX INC · $14.73M
  • GHRS GH Research PLC · $14.09M
  • ACRS Aclaris Therapeutics, Inc. · $10.65M
  • CBIO Crescent Biopharma, Inc. · $5.84M
  • WSE Wise Group PLC · $4.02M

Fully Exited (vs previous quarter)

  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $66.77M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $53.17M
  • COF CAPITAL ONE FINL CORP · prev qtr: $34.43M
  • SION SIONNA THERAPEUTICS INC COM · prev qtr: $26.86M
  • ORKA ORUKA THERAPEUTICS INC · prev qtr: $23.79M
  • MPLT MAPLIGHT THERAPEUTICS INC · prev qtr: $16.13M
  • PDD PDD HOLDINGS INC · prev qtr: $7.25M
  • AAPL APPLE INC · prev qtr: $6.66M

Insider Transactions (Form 4)

Latest Siren, L.L.C. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Siren, L.L.C. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 116 positions worth $4.93B in total. HoldingsHub carries 8 quarters of its filings (Q3 2024–Q2 2026).

Portfolio Structure

  • 116 positions · $4.93B reported value (Q2 2026)
  • Top 10 holdings = 44.8% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 10.7%
  • Average position size: $42.48M

Sector Tilt

  • Health Care 92.0%
  • Information Technology 4.5%
  • Consumer Discretionary 1.2%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 25 new, 32 added, 21 reduced, 9 exited
  • 38 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively reducing exposure to most top-10 holdings (7/10) while selectively adding to a few, suggesting a cautious stance on current biotech/healthcare positions but targeted bets on specific catalysts. 2. Key moves: - Added: ERAS (+15.8% shares), TNGX (+9.8%), ARWR (+33.5%) - Reduced: SRRK (-2.1%), KYMR (-5.1%), RVMD (-5.6%), MANE (-20.0%), EWTX (-11.9%), RYTM (-4.4%) - Hold: ONC (no change) 3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with high risk appetite (small-cap biotech/therapeutics). 4. Per-holding one-liner: - SRRK: Scholar Rock (biopharma, unverified) - KYMR: Kymera Therapeutics (drug discovery, unverified) - ERAS: Erasca (cancer therapeutics, unverified) - RVMD: Revolution Medicines (cancer R&D, unverified) - ONC: BEONE MEDICINES (oncology, unverified) - TNGX: Tango Therapeutics (cancer genomics, unverified) - MANE: Veradermics (dermatology, unverified) - ARWR: Arrowhead Pharmaceuticals (gene therapy, unverified) - EWTX: Edgewise Therapeutics (muscle disorders, unverified) - RYTM: Rhythm Pharmaceuticals (obesity/rare disease, unverified) 5. Style summary: Cautiously selective biotech fund trimming broadly while doubling down on high-conviction catalysts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 04:12

Sector Allocation

Health Care 94.0%
Technology 4.2%
Financials 0.2%
Energy 0.0%
Other 0.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 9.38M $453.00M 10.76%
10.76%
Reduce
2 2.78M $311.32M 7.39%
7.39%
Reduce
3 13.20M $193.48M 4.60%
4.60%
Add
4 850.00K $174.47M 4.14%
4.14%
Reduce
5 465.00K $170.16M 4.04%
4.04%
Hold
6 6.78M $169.26M 4.02%
4.02%
Add
7 1.32M $160.54M 3.81%
3.81%
Reduce
8 2.29M $149.91M 3.56%
3.56%
Add
9 2.80M $113.85M 2.70%
2.70%
Reduce
10 1.09M $103.43M 2.46%
2.46%
Reduce
11 5.50M $102.41M 2.43%
2.43%
Reduce
12 2.99M $96.62M 2.29%
2.29%
Hold
13 44.30M $83.29M 1.98%
1.98%
Hold
14 868.60K $77.33M 1.84%
1.84%
Reduce
15 3.40M $74.27M 1.76%
1.76%
Add
16 2.37M $72.97M 1.73%
1.73%
Add
17 2.48M $72.19M 1.72%
1.72%
Add
18 1.48M $67.62M 1.61%
1.61%
Reduce
19 1.70M $66.52M 1.58%
1.58%
Reduce
20 2.42M $62.52M 1.49%
1.49%
Hold
21 3.26M $58.90M 1.40%
1.40%
Reduce
22 888.40K $58.15M 1.38%
1.38%
Hold
23 7.69M $55.60M 1.32%
1.32%
Hold
24 2.00M $51.88M 1.23%
1.23%
Hold
25 1.61M $51.53M 1.22%
1.22%
Reduce
26 9.85M $47.95M 1.14%
1.14%
Hold
27 708.95K $46.73M 1.11%
1.11%
Reduce
28 3.36M $45.23M 1.07%
1.07%
Add
29 4.86M $41.96M 1.00%
1.00%
Hold
30 2.43M $39.13M 0.93%
0.93%
Add
31 1.93M $38.40M 0.91%
0.91%
New
32 1.54M $32.93M 0.78%
0.78%
Hold
33 2.89M $31.56M 0.75%
0.75%
Reduce
34 130.00K $29.62M 0.70%
0.70%
New
35 1.40M $28.87M 0.69%
0.69%
Hold
36 207.49K $28.62M 0.68%
0.68%
Reduce
37 2.36M $27.71M 0.66%
0.66%
Add
38 1.79M $27.53M 0.65%
0.65%
Reduce
39 80.00K $27.53M 0.65%
0.65%
Reduce
40 872.97K $27.30M 0.65%
0.65%
Hold
41 718.31K $26.71M 0.64%
0.64%
Reduce
42 2.21M $25.29M 0.60%
0.60%
Hold
43 2.42M $24.02M 0.57%
0.57%
Add
44 97.50K $22.27M 0.53%
0.53%
Add
45 1.10M $22.09M 0.53%
0.53%
Hold
46 1.52M $21.82M 0.52%
0.52%
Reduce
47 641.47K $21.55M 0.51%
0.51%
Hold
48 270.12K $21.52M 0.51%
0.51%
Hold
49 45.00K $20.53M 0.49%
0.49%
Add
50 900.00K $19.15M 0.46%
0.46%
Hold

FAQ

What did Siren, L.L.C. buy in 2026-Q3?

In its 2026-Q3 13F filing, Siren, L.L.C. reported 109 equity positions worth $4.21B in aggregate; its largest disclosed positions were SRRK ($453.00M), KYMR ($311.32M), ERAS ($193.48M).

How large is Siren, L.L.C.'s portfolio?

Siren, L.L.C. reported $4.21B of long equity holdings across 109 positions as of 2026-Q3. Top-10 holdings account for 47.5% of reported value.

What is Siren, L.L.C.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/siren/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →